BACKGROUND: IL-13 is a key mediator of allergic asthma. IL-13 mediates its effects via its receptor, a heterodimer composed of IL-4R alpha and IL-13R alpha1. Polymorphic variants of both IL-13 and IL-4R alpha have been shown to be associated with atopy. OBJECTIVE: We examined the functional consequences of the Q110 IL-13 variant in vitro and in vivo to determine whether it displays enhanced functional activity compared with R110 IL-13, both in the context of I50Q551 IL-4R alpha and of the atopy-associated variant V50R551 IL-4R alpha. METHODS: We used a mouse cell line stably expressing human IL-4R alpha and IL-13R alpha1 that readily responds to human IL-4 and IL-13. For in vivo analyses, we used BALB/c mice. RESULTS: The Q110 IL-13 variant displayed significantly increased activity compared with R110 IL-13. Furthermore, mice treated with Q110 IL-13 variant displayed increased airways hyperresponsiveness relative to R110 IL-13. We then examined the functional consequences of Q110 IL-13 variant in combination with an atopy-associated variant of its receptor, IL-4R alpha (V50R551). Q110 IL-13 variant had increased activity on these cells as well, and, strikingly, the effect was greater than that observed in cells expressing I50Q551 IL-4R alpha. CONCLUSION: Either Q110 IL-13 variant or V50R551 IL-4R alpha variant has enhanced function alone, but the 2 together have a synergistic effect on IL-13-dependent gene induction. Our data demonstrate the importance of relatively small individual differences in gene products from common single nucleotide polymorphisms that may result in larger combined differences. Furthermore, a relatively modest change in function from a single nucleotide polymorphism can result in an important biological difference in vivo.
BACKGROUND:IL-13 is a key mediator of allergic asthma. IL-13 mediates its effects via its receptor, a heterodimer composed of IL-4R alpha and IL-13R alpha1. Polymorphic variants of both IL-13 and IL-4R alpha have been shown to be associated with atopy. OBJECTIVE: We examined the functional consequences of the Q110 IL-13 variant in vitro and in vivo to determine whether it displays enhanced functional activity compared with R110 IL-13, both in the context of I50Q551 IL-4R alpha and of the atopy-associated variant V50R551 IL-4R alpha. METHODS: We used a mouse cell line stably expressing humanIL-4R alpha and IL-13R alpha1 that readily responds to humanIL-4 and IL-13. For in vivo analyses, we used BALB/c mice. RESULTS: The Q110 IL-13 variant displayed significantly increased activity compared with R110 IL-13. Furthermore, mice treated with Q110 IL-13 variant displayed increased airways hyperresponsiveness relative to R110 IL-13. We then examined the functional consequences of Q110 IL-13 variant in combination with an atopy-associated variant of its receptor, IL-4R alpha (V50R551). Q110 IL-13 variant had increased activity on these cells as well, and, strikingly, the effect was greater than that observed in cells expressing I50Q551 IL-4R alpha. CONCLUSION: Either Q110 IL-13 variant or V50R551 IL-4R alpha variant has enhanced function alone, but the 2 together have a synergistic effect on IL-13-dependent gene induction. Our data demonstrate the importance of relatively small individual differences in gene products from common single nucleotide polymorphisms that may result in larger combined differences. Furthermore, a relatively modest change in function from a single nucleotide polymorphism can result in an important biological difference in vivo.
Authors: Frank D Vladich; Susan M Brazille; Debra Stern; Michael L Peck; Raffaella Ghittoni; Donata Vercelli Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp Journal: J Immunol Date: 2010-02-15 Impact factor: 5.422
Authors: Alan P Knutsen; Hari M Vijay; Barbara Kariuki; Luis A Santiago; Ralph Graff; Jonathan D Wofford; Maulik R Shah Journal: Clin Mol Allergy Date: 2010-03-18
Authors: Michael E Scheurer; E Amirian; Yumei Cao; Mark R Gilbert; Kenneth D Aldape; David G Kornguth; Randa El-Zein; Melissa L Bondy Journal: Clin Cancer Res Date: 2008-10-15 Impact factor: 12.531
Authors: Rebecca E Slager; Gregory A Hawkins; Xingnan Li; Dirkje S Postma; Deborah A Meyers; Eugene R Bleecker Journal: Clin Chest Med Date: 2012-07-07 Impact factor: 2.878
Authors: Weiguo Chen; Umasundari Sivaprasad; Aaron M Gibson; Mark B Ericksen; Christie M Cunningham; Stacey A Bass; Kayla G Kinker; Fred D Finkelman; Marsha Wills-Karp; Gurjit K Khurana Hershey Journal: J Allergy Clin Immunol Date: 2013-06-12 Impact factor: 10.793